Neurodex at the Bio-Neuroscience Conference

Neurodex at the Bio-Neuroscience Conference

Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…

Neurodex to Participate in 2nd Annual AAEV Meeting: Exploring the Potential of Extracellular Vesicles

Neurodex to Participate in 2nd Annual AAEV Meeting: Exploring the Potential of Extracellular Vesicles

Introduction: Neurodex is pleased to announce its participation in the upcoming 2nd Annual Meeting hosted by the American Association of Extracellular Vesicles (AAEV). Set against the picturesque backdrop of Boston, MA, this event promises to gather esteemed experts in extracellular vesicle research. Neurodex is gearing up to share its latest insights into the study of…

Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…

FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, Leqembi

FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, Leqembi

Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…

NeuroDex, Inc., Announces Award from The Michael J. Fox Foundation

NeuroDex, Inc., Announces Award from The Michael J. Fox Foundation

For application titled: “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles”NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, January 26, 2023 /EINPresswire.com/ — NeuroDex, Inc.(“NeuroDex”, or the “Company”), announces that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study, “Blood Test for Parkinson’s Stratification based on Neuron…